secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2021-09-29T23:59:59+00:00
Accession:  0000950170-21-001925
Event type: leadership
Sentiment:  positive
Materiality: 0.35
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou Biosciences appoints Ran Zheng to board of directors
------------------------------------------------------------

- Board increased from 5 to 6 directors; Zheng appointed Class I director and to Nominating Committee.
- Zheng receives $40,000/yr board cash compensation plus $4,000/yr committee cash compensation.
- Initial grant of 44,000 non-qualified stock options, vesting over 3 years starting Oct 1, 2022.
- Zheng brings 25+ years biotech experience, most recently CEO of Landmark Bio and CTO at Orchard Therapeutics.
- Press release issued Sep 29, 2021; option exercise price = closing price on Oct 1, 2021 grant date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000095017021001925/0000950170-21-001925-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000095017021001925/crbu-20210924.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-001925

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer